Mymd Pharmaceuticals IncNASDAQ:MYMD
- LAST PRICE2.3500
- TODAY'S CHANGE (%)0.1600 (7.3059%)
- Bid / Lots2.2700/ 3
- Ask / Lots2.3200/ 2
- Open / Previous Close2.2000 / 2.1900
- Day Range
- 52 Week Range
- Volume16,727
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MYMD |
|---|---|---|
| 09:32 ET | 349 | 2.2 |
| 09:45 ET | 400 | 2.24 |
| 09:50 ET | 143 | 2.23 |
| 09:56 ET | 600 | 2.2176 |
| 10:03 ET | 542 | 2.2101 |
| 10:06 ET | 600 | 2.2146 |
| 10:10 ET | 100 | 2.2399 |
| 10:32 ET | 3168 | 2.25 |
| 10:33 ET | 2347 | 2.26 |
| 11:20 ET | 1772 | 2.275 |
| 12:02 ET | 100 | 2.28 |
| 12:14 ET | 166 | 2.2641 |
| 12:21 ET | 499 | 2.27 |
| 12:45 ET | 250 | 2.28 |
| 12:52 ET | 100 | 2.285 |
| 01:06 ET | 850 | 2.3 |
| 01:32 ET | 110 | 2.29 |
| 01:39 ET | 150 | 2.325 |
| 01:46 ET | 500 | 2.363 |
| 02:22 ET | 440 | 2.29 |
| 03:18 ET | 166 | 2.335 |
| 03:38 ET | 298 | 2.321 |
| 03:48 ET | 100 | 2.34 |
| 03:57 ET | 100 | 2.35 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mymd Pharmaceuticals Inc | 5.4M | -0.4x | --- |
Genprex Inc | 5.4M | -0.1x | --- |
Lixte Biotechnology Holdings Inc | 5.5M | -1.0x | --- |
CeCors Inc | 5.2M | 0.0x | --- |
ProtoKinetix Inc | 5.2M | -12.0x | --- |
HST Global Inc | 5.8M | -39.5x | --- |
Company Information
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Contact Information
- Headquarters
- 855 N. Wolfe Street, Suite 601BALTIMORE, MD, United States 21205
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Joshua Silverman
- President, Director, Chief Medical Officer
- Chris Chapman
- Interim Chief Financial Officer
- Ian Rhodes
- Executive Vice President - Operations, General Counsel, Chief Legal Officer
- Paul Rivard
- Chief Scientific Officer
- Adam Kaplin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.08 |
EPS | $-5.53 |
Book Value | $11.17 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
